专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US5877318A Hydroquinone derivative and pharmaceutical use thereof 失效
标题翻译：对苯二酚衍生物及其药物用途
公开(公告)号：US5877318A
公开(公告)日：1999-03-02
申请号：US113826
申请日：1998-07-10
申请人： Yoshiaki Isobe , Yuso Goto , Masanori Tobe , Osamu Takahashi
发明人： Yoshiaki Isobe , Yuso Goto , Masanori Tobe , Osamu Takahashi
IPC分类号： C07D239/54 , C07D239/545 , C07D405/12
CPC分类号： C07D239/545 , C07D405/12
摘要： Disclosed is a hydroquinone derivative or a pharmaceutically acceptable salt thereof, the hydroquinone derivative being represented by formula (I): ##STR1## wherein R.sup.1 is a phenyl group which is unsubstituted or substituted with a substituent or substituents each independently selected from the group consisting of a halogen atom, a C1-4 alkyl group and a C1-4 alkoxy group;R.sup.2 is a hydrogen atom or a C1-4 alkyl group;each of R.sup.3 and R.sup.4 is independently a hydrogen atom or a C1-4 alkyl group;R.sup.5 is a hydrogen atom or a C1-4 alkyl group;each of R.sup.6, R.sup.7 and R.sup.8 is independently a hydrogen atom or a C1-4 alkyl group;P is a hydroxyl group;Q is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group;P may form together with Q an ether bond;R is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group, provided that when one of said Q and said R is an oxo group, the other is also an oxo group;X is a single bond, an --NR.sup.10 -- group or a --CH.sub.2 --NR.sup.10 -- group in which R.sup.10 is a hydrogen atom or a C1-4 alkyl group;Y is a methylene group or a carbonyl group; anddotted bonds in a six membered ring represent that said six membered ring has the maximum number of double bonds.
摘要翻译：公开了氢醌衍生物或其药学上可接受的盐，氢醌衍生物由式（I）表示：未取代或被各自独立地选自卤素原子，C 1-4烷基的取代基或取代基取代和C 1-4烷氧基; R2是氢原子或C1-4烷基; R 3和R 4各自独立地为氢原子或C 1-4烷基; R5是氢原子或C1-4烷基; R6，R7和R8各自独立地为氢原子或C1-4烷基; P是羟基; Q是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基; P可与Q形成醚键; R是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基，条件是当所述Q和所述R中的一个是氧代基时，另一个也是氧代基; X是单键，-NR 10 - 基或-CH 2 -NR 10 - 基，其中R 10是氢原子或C 1-4烷基; Y是亚甲基或羰基; 六元环中的点状键表示所述六元环具有最大数量的双键。

22. 发明申请

US20060094737A1 Novel uracil derivatives and medicinal use thereof 审中-公开
标题翻译：新型尿嘧啶衍生物及其药用
公开(公告)号：US20060094737A1
公开(公告)日：2006-05-04
申请号：US10528373
申请日：2003-09-17
申请人： Yoshiaki Isobe , Masanori Tobe , Yoshifumi Inoue , Masakazu Isobe
发明人： Yoshiaki Isobe , Masanori Tobe , Yoshifumi Inoue , Masakazu Isobe
IPC分类号： A61K31/513 , C07D405/02 , C07D239/54
CPC分类号： C07D239/545 , A61K31/513 , C07D405/06 , C07D405/12 , C07D405/14
摘要： It is intended to provide an uracil derivative represented by the following general formula (I): (I) wherein X represents a group selected from among NHCO, NHCH2, CO, CONH and CH2NH; R1 represents hydrogen or optionally substituted C1-6 alkyl; R2 represents a group of the following general formula (II) or (III): (II) (III) (wherein m is 0 or 1; n is an integer of from 1 to 3; Y represents OH or NH2; and a dotted line shows a binding position), provided that when R2 is a group of the general formula (III), X represents NHCO or NHCH2; R3 and R4 independently represent each hydrogen or C1-6 alkyl; and Ar represents phenyl substituted by C1-6 alkyl at the o- and m-positions, optionally substituted heteroaryl or a bicyclic aromatic group; its pharmaceutically acceptable salt, and a remedy containing the above uracil derivative or its pharmaceutically acceptable salt as the active ingredient for, in particular, allergic diseases relating to a type IV allergic reaction, i.e., a novel compound useful in treating diseases in which a type IV allergic reaction participates and a remedy for allergic diseases containing the same as the active ingredient.
摘要翻译：旨在提供由以下通式（I）表示的尿嘧啶衍生物：（I）其中X表示选自NHCO，NHCH 2，CO，CONH和CH 2的基团 NH; R 1表示氢或任选取代的C 1-6烷基; R 2表示下述通式（II）或（III）的基团：（II）（III）（其中m为0或1; n为1至3的整数; Y 表示OH或NH 2，虚线表示结合位置），条件是当R 2为通式（III）的基团时，X表示NHCO或 NHCH 2

23. 发明授权

US5821247A Hydroquinone derivative and pharmaceutical use thereof 失效
标题翻译：对苯二酚衍生物及其药物用途
公开(公告)号：US5821247A
公开(公告)日：1998-10-13
申请号：US933208
申请日：1997-09-16
申请人： Yoshiaki Isobe , Yuso Goto , Masanori Tobe , Osamu Takahashi
发明人： Yoshiaki Isobe , Yuso Goto , Masanori Tobe , Osamu Takahashi
IPC分类号： C07D239/54 , C07D239/545 , C07D405/12 , A61K31/51
CPC分类号： C07D239/545 , C07D405/12
摘要： Disclosed is a hydroquinone derivative or a pharmaceutically acceptable salt thereof, the hydroquinone derivative being represented by formula (I): ##STR1## wherein R.sup.1 is a phenyl group which is unsubstituted or substituted with a substituent or substituents each independently selected from the group consisting of a halogen atom, a C1-4 alkyl group and a C1-4 alkoxy group; R.sup.2 is a hydrogen atom or a C1-4 alkyl group; each of R.sup.3 and R.sup.4 is independently a hydrogen atom or a C1-4 alkyl group; R.sup.5 is a hydrogen atom or a C1-4 alkyl group; each of R.sup.6, R.sup.7 and R.sup.8 is independently a hydrogen atom or a C1-4 alkyl group; P is a hydroxyl group; Q is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group; P may form together with Q an ether bond; R is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group, provided that when one of said Q and said R is an oxo group, the other is also an oxo group; X is a single bond, an --NR.sup.10 --group or a --CH.sub.2 --NR.sup.10 --group in which R.sup.10 is a hydrogen atom or a C1-4 alkyl group; Y is a methylene group or a carbonyl group; and dotted bonds in a six membered ring represent that said six membered ring has the maximum number of double bonds.
摘要翻译：公开了氢醌衍生物或其药学上可接受的盐，所述对苯二酚衍生物由式（I）表示：未取代的或被各自独立地选自卤素原子，C 1-4烷基的取代基或取代基取代和C 1-4烷氧基; R2是氢原子或C1-4烷基; R 3和R 4各自独立地为氢原子或C 1-4烷基; R5是氢原子或C1-4烷基; R6，R7和R8各自独立地为氢原子或C1-4烷基; P是羟基; Q是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基; P可与Q形成醚键; R是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基，条件是当所述Q和所述R中的一个是氧代基时，另一个也是氧代基; X是单键，-NR 10 - 基或-CH 2 -NR 10 - 基，其中R 10是氢原子或C 1-4烷基; Y是亚甲基或羰基; 六元环中的点状键表示所述六元环具有最大数量的双键。

24. 发明授权

US08476288B2 Salts 756 有权
标题翻译：盐756
公开(公告)号：US08476288B2
公开(公告)日：2013-07-02
申请号：US12784226
申请日：2010-05-20
申请人： Nicholas James Bennett , Thomas McInally , Austen Pimm , Yoshiaki Isobe
发明人： Nicholas James Bennett , Thomas McInally , Austen Pimm , Yoshiaki Isobe
IPC分类号： A61K31/505 , C07D239/48
CPC分类号： C07D239/49 , C07D275/06
摘要： The invention provides salts of 4-(dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate, pharmaceutical compositions containing them and their use in therapy.
摘要翻译：本发明提供2-（4 - （（2-氨基-4-甲基-6-（戊基氨基）嘧啶-5-基）甲基）苯基）乙酸4-（二甲基氨基）丁酯的盐，含有它们的药物组合物及其用途在治疗。

25. 发明申请

US20100099870A1 NOVEL ADENINE COMPOUND 失效
标题翻译：新颖的化合物
公开(公告)号：US20100099870A1
公开(公告)日：2010-04-22
申请号：US12531867
申请日：2008-03-19
申请人： Yoshiaki Isobe , Tomoaki Nakamura
发明人： Yoshiaki Isobe , Tomoaki Nakamura
IPC分类号： C07D473/18
CPC分类号： C07D473/18 , C07D473/00
摘要： A novel adenine compound represented by the formula (1): [wherein R1 is substituted or unsubstituted alkyl, etc., X is oxygen, etc., A1 is 4- to 8-membered substituted or unsubstituted saturated nitrogen-containing heterocycle containing 1 to 2 hetero atom(s) selected from 1 to 2 nitrogen(s), 0 to 1 oxygen and 0 to 1 sulfur, etc., A2 is substituted or unsubstituted 6- to 10-membered aryl, etc., L1 and L2 are independently a straight chain or branched chain alkylene, etc.], or a pharmaceutically acceptable salt thereof, which is useful as a medicament.
摘要翻译：由式（1）表示的新型腺嘌呤化合物：其中，R 1为取代或未取代的烷基等，X为氧等，A 1为4〜8元的取代或未取代的饱和含氮杂环， 2个选自1至2个氮，0至1个氧和0至1个硫等的杂原子，A2为取代或未取代的6-至10-元芳基等，L1和L2独立地为直链或支链亚烷基等]或其药学上可接受的盐，其可用作药物。

26. 发明申请

US20100011423A1 User identification system and a method thereof 有权
标题翻译：用户识别系统及其方法
公开(公告)号：US20100011423A1
公开(公告)日：2010-01-14
申请号：US12379639
申请日：2009-02-26
申请人： Yoshiaki Isobe , Takao Murakami , Kenta Takahashi
发明人： Yoshiaki Isobe , Takao Murakami , Kenta Takahashi
IPC分类号： H04L9/32 , G06F21/00
CPC分类号： G06F21/32 , G06F21/31 , G07C9/00158
摘要： A service providing system using the biometrics identification without inputting the user ID poses the problem that the consideration of a service is erroneously claimed to the registered user not using the service due to the erroneous identification. According to this invention, the threshold of the value of the degree of similarity for user identification is set strictly for each registered biometrics information of the user in accordance with the declaration of the loss caused by the erroneous identification.
摘要翻译：在不输入用户ID的情况下使用生物特征识别的服务提供系统造成了由于错误识别而使服务错误地要求给注册用户不使用服务的问题。根据本发明，根据由错误识别引起的损失的声明，对用户的每个登记生物特征信息严格地设定用户识别度的相似度值的阈值。

27. 发明申请

US20090307764A1 Biometric Authenticaton System and Method with Vulnerability Verification 失效
标题翻译：生物特征识别系统和脆弱性验证方法
公开(公告)号：US20090307764A1
公开(公告)日：2009-12-10
申请号：US12293470
申请日：2007-03-23
申请人： Yoshiaki Isobe , Masahiro Mimura
发明人： Yoshiaki Isobe , Masahiro Mimura
IPC分类号： H04L9/32 , G06F21/20
CPC分类号： G06F21/32 , G06F21/51 , G06F21/577 , G06F2221/2101 , H04L9/3231
摘要： A biometric authentication device has a threat of an attack of pretending to be someone else by such as forgery. The present invention supports a service provider to appropriately decide the level of such threat.A vulnerability verification server 150 is provided in the system, and the vulnerability of each biometric product is centrally managed. A service provider 130 sends the information that specifies the device in which a client terminal 110 executes the biometric authentication to the vulnerability verification server 150, and receives the vulnerability information. The service provider 130 decides whether the service can be provided or not to the client terminal 110 using the vulnerability information that was received.
摘要翻译：生物识别认证设备有伪装的假冒伪装的威胁。本发明支持服务提供商适当地确定这种威胁的程度。系统中提供了一个漏洞验证服务器150，并且集中管理每个生物特征产品的漏洞。服务提供者130将指定客户终端110的设备的信息发送到漏洞验证服务器150，并接收该漏洞信息。服务提供者130使用接收到的漏洞信息来判定是否可以向客户终端110提供服务。

28. 发明申请

US20090082332A1 PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS 审中-公开
标题翻译：用于治疗病毒或过敏性疾病和癌症的嘌呤衍生物
公开(公告)号：US20090082332A1
公开(公告)日：2009-03-26
申请号：US12067536
申请日：2006-09-20
申请人： Philip Abbot , Roger Victor Bonnert , Stephen Brough , Kamaldeep Chohan , Thomas McInally , Stephen Thom , Yoshiaki Isobe , Kei Nakamura , Shingo Tojo
发明人： Philip Abbot , Roger Victor Bonnert , Stephen Brough , Kamaldeep Chohan , Thomas McInally , Stephen Thom , Yoshiaki Isobe , Kei Nakamura , Shingo Tojo
IPC分类号： A61K31/397 , C07D473/02 , A61P31/12 , A61P35/00 , A61P37/08 , A61K31/522
CPC分类号： C07D473/34
摘要： The present invention provides compounds of formula (I) wherein R1, Y1, X1, Z1, X2, Y2, A, Y3, n, R and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
摘要翻译：本发明提供式（I）化合物，其中R1，Y1，X1，Z1，X2，Y2，A，Y3，n，R和R2如说明书中所定义，其制备方法，含有它们的药物组合物及其制备方法用于治疗。

29. 发明申请

US20110185176A1 BIOMETRIC AUTHENTICATION METHOD AND SYSTEM 有权
标题翻译：生物识别方法与系统
公开(公告)号：US20110185176A1
公开(公告)日：2011-07-28
申请号：US13057468
申请日：2009-08-21
申请人： Kenta Takahashi , Shinji Hirata , Yoshiaki Isobe
发明人： Kenta Takahashi , Shinji Hirata , Yoshiaki Isobe
IPC分类号： H04L9/32
CPC分类号： H04L63/0861 , G06F21/32 , G06F21/83 , G06F2221/2153 , G06K2009/00953 , G07C9/00158 , G07C9/00166 , G07C2209/12 , H04L9/3231 , H04L2209/043
摘要： At a registration time, a feature data array for registration is generated from biometric information acquired by a client, and a position correction template and a comparison template obtained by converting the feature data array for registration are registered in a server.At an authentication time, a feature data array for authentication is generated from biometric information acquired by the client, and converted feature data for position correction obtained by converting the feature data array for authentication is transmitted to the server. The server detects a position correction amount of the feature data array for authentication relative to the feature data array for registration using the position correction template and the converted feature data for position correction, and transmits the position correction amount to the client. The client corrects the feature data array for authentication using the position correction amount and transmits the converted feature data array for comparison to the server. The server calculates a distance between the comparison template and the converted feature data array for comparison and determines success or failure of the authentication on the basis of the distance.
摘要翻译：在注册时，由客户机获取的生物特征信息生成用于注册的特征数据阵列，并且通过转换用于注册的特征数据阵列获得的位置校正模板和比较模板被登记在服务器中。在认证时刻，由客户端获取的生物特征信息生成用于认证的特征数据阵列，并且将用于认证的特征数据阵列转换获得的用于位置校正的转换特征数据发送到服务器。服务器使用位置校正模板和转换后的位置校正特征数据检测相对于用于登记的特征数据阵列进行认证的特征数据阵列的位置校正量，并将位置校正量发送给客户端。客户端使用位置校正量来校正特征数据阵列进行认证，并将转换的特征数据数组发送到服务器进行比较。服务器计算比较模板和转换的特征数据阵列之间的距离进行比较，并根据距离确定认证的成功或失败。

30. 发明申请

US20110136801A1 Novel Compounds 审中-公开
标题翻译：新型化合物
公开(公告)号：US20110136801A1
公开(公告)日：2011-06-09
申请号：US12958846
申请日：2010-12-02
申请人： Yoshiaki Isobe , Mai Kasai , Tomoaki Nakamura , Shingo Tojo , Hirotaka Kurebayashi
发明人： Yoshiaki Isobe , Mai Kasai , Tomoaki Nakamura , Shingo Tojo , Hirotaka Kurebayashi
IPC分类号： A61K31/4745 , C07D471/04 , A61K31/496 , A61K31/5377 , A61P35/00 , A61P31/04 , A61P31/12 , A61P11/06 , A61P17/00 , A61P31/18 , A61P31/20 , A61P31/14
CPC分类号： C07D471/04
摘要： The present invention provides compounds of formula (I): wherein Ra, Rb, Rc, R1, R2, R3, X1, Y1, Z1, A, n and m are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
摘要翻译：本发明提供式（I）化合物：其中Ra，Rb，Rc，R 1，R 2，R 3，X 1，Y 1，Z 1，A，n和m如说明书中所定义，及其药学上可接受的盐作为其制备方法，含有它们的药物组合物及其在治疗中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式